Skip to content

Safety and efficacy of hydrogen peroxide lavage during endoscopic treatments for walled-off necrosis

Safety and efficacy of hydrogen peroxide lavage during endoscopic treatments for walled-off necrosis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031220696
Enrollment
10
Registered
2023-03-13
Start date
2023-04-27
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

walled-off necrosis (WON) WON

Interventions

Off-label use of hydrogen peroxide during endoscopic treatments for WON

Sponsors

Takahara Naminatsu
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Diagnose with WON by contrast CT based on revised Atlanta classification (diagnosis by non-contrast CT or MRI is allowed if participants have contraindications for contrast CT) (2) Judged to be treated with drainage due to symptoms: fever, stomach pain, bloating or other bowel obstruction symptoms, jaundice (3) Aged 18 years and above at the time of informed consent (4) Male or female (5) Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation

Exclusion criteria

Exclusion criteria: (1) Not suitable for endoscopy, as follows: 1. Judge that endoscopic and percutaneous approaches to WON are impossible by clinical investigators 2. With hemorrhagic diathesis: platelet 1.5 3. Taking antithrombotic therapy and unable to stop or change the antithrombotic drugs following Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment 4. Judged that it is impossible to perform endoscopic and percutaneous treatment safely by clinical investigators (2) With a history of severe drug allergy including anaphylactic shock, or a history of severe side effects (3) With allergy to components of study drug (4) Judged as ineligible by clinical investigators

Design outcomes

Primary

MeasureTime frame
Incidence of moderate or severe adverse events during hospitalization

Secondary

MeasureTime frame
(1) Rate of clinical success (defined as lesion shrinkage and symptom improvement) (2) Length of treatment (3) Incidence of clinical events (4) Length of hospitalization (5) Incidence of adverse events

Contacts

Public ContactTomotaka Saito

The University of Tokyo Hospital

tomsaito623@gmail.com+81-338155411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026